EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of immunocompetent models for primary and metastatic ER + breast cancer

Devon M Bull iD, Jody Hazlett, Emily Schulpen, Sophie Tunnicliffe, Alexander D McLellan, Anita K Dunbier

Animal Models and Experimental Medicine · 2026-05 · 9 (5) · 866-878

DOI: 10.1002/ame2.70210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, online erschienen am 12.05.2026. Verfasst von Devon M Bull und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Receptors, Estrogen, Breast Neoplasms, Disease Models, Animal, Mammary Neoplasms, Experimental. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otago Medical Research Foundation (New Zealand), Cancer Research Trust (New Zealand).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The development of effective therapeutic strategies for late‐stage estrogen receptor‐positive breast cancer (ER+) is limited by the scarcity of biologically relevant models. More recently, immunotherapies emerged as promising candidates for breast cancer treatment, however, the absence of immunocompetent models of ER+ breast cancer metastasis continues to hinder the assessment of these theraputic interventions.

Methods

To address this, we utilized the 129S6/SvEv mouse strain and syngeneic SSM3 cells in the assessment and development of ER+ metastasis models. As part of this study, the mammary intraductal (MIND) primary tumor model was established in the same background. In addition, a novel luciferase system was evaluated for potential use in metastasis tracking.

Results

Luciferase‐expressing SSM3 cells enabled longitudinal in vivo imaging to track tumor growth. Histological analysis confirmed metastatic spread and tumor origin. Antares2, a novel luciferase reporter, showed high in vitro sensitivity but reduced in vivo performance. The study showed that systemic delivery of SSM3 cells with oestradiol supplementation can support metastatic tumor establishment and that MIND injections led to reliable, invasive tumor growth.

Conclusions

These findings highlight the potential and limitations of the 129S6/SvEv model as a syngeneic, immunocompetent system for studying ER+ breast cancer metastasis. Reporter expression may affect immunogenicity or cell fitness. Further refinement of these models will enable investigation of immune‐modulatory therapies in ER+ metastatic breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, EstrogenBreast NeoplasmsDisease Models, AnimalMammary Neoplasms, ExperimentalAnimalsFemaleMiceCell Line, TumorNeoplasm MetastasisImmunocompetenceHumans

Stichwörter der Autor:innen

breast cancerestrogen receptor positiveimmunocompetent modelmetastasis

Substanzen

Receptors, Estrogen

Autor:innen und Institutionen

  • Department of Biochemistry, University of Otago, Dunedin, New Zealand.
  • Department of Pathology and Biomedical Sciences, University of Otago, Christchurch, New Zealand.
  • Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.

ORCID-Profile: Devon M Bull

Förderung

  • Otago Medical Research Foundation (New Zealand)
  • Cancer Research Trust (New Zealand)

Zitieren

APA

Bull, D. M., Hazlett, J., Schulpen, E., Tunnicliffe, S., McLellan, A. D., & Dunbier, A. K. (2026). Development of immunocompetent models for primary and metastatic ER + breast cancer. Animal Models and Experimental Medicine, 9(5), 866-878. https://doi.org/10.1002/ame2.70210

Vancouver

Bull DM, Hazlett J, Schulpen E, Tunnicliffe S, McLellan AD, Dunbier AK. Development of immunocompetent models for primary and metastatic ER + breast cancer. Animal Models and Experimental Medicine. 2026;9(5):866-878. doi:10.1002/ame2.70210

BibTeX
@article{Bull2026,
  author = {Bull, Devon M and Hazlett, Jody and Schulpen, Emily and Tunnicliffe, Sophie and McLellan, Alexander D and Dunbier, Anita K},
  title = {Development of immunocompetent models for primary and metastatic ER + breast cancer},
  journal = {Animal Models and Experimental Medicine},
  year = {2026},
  volume = {9},
  number = {5},
  pages = {866--878},
  doi = {10.1002/ame2.70210}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche